Metagenomi Therapeutics Debt to Equity Ratio 2022-2026 | MGX
Current and historical debt to equity ratio values for Metagenomi Therapeutics (MGX) over the last 10 years. The debt/equity ratio can be defined as a measure of a company's financial leverage calculated by dividing its long-term debt by stockholders' equity. Metagenomi Therapeutics debt/equity for the three months ending March 31, 2026 was 0.00.
| Metagenomi Therapeutics Debt/Equity Ratio Historical Data | |||
|---|---|---|---|
| Date | Long Term Debt | Shareholder's Equity | Debt to Equity Ratio |
| 2026-03-31 | $0.06B | $0.14B | 0.43 |
| 2025-12-31 | $0.06B | $0.16B | 0.39 |
| 2025-09-30 | $0.07B | $0.18B | 0.39 |
| 2025-06-30 | $0.08B | $0.20B | 0.39 |
| 2025-03-31 | $0.09B | $0.21B | 0.40 |
| 2024-12-31 | $0.09B | $0.24B | 0.38 |
| 2024-09-30 | $0.10B | $0.26B | 0.40 |
| 2024-06-30 | $0.12B | $0.27B | 0.43 |
| 2024-03-31 | $0.14B | $0.28B | 0.51 |
| 2023-12-31 | $0.15B | $0.22B | 0.70 |
| 2023-09-30 | $0.00B | $0.00B | 0.00 |
| 2023-06-30 | $0.00B | $0.00B | 0.00 |
| 2023-03-31 | $0.00B | $0.00B | 0.00 |
| 2022-12-31 | $0.14B | $0.27B | 0.53 |
| 2021-12-31 | $0.10B | $0.04B | 2.23 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $0.052B | $0.025B |
| Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| BridgeBio Pharma (BBIO) | United States | $14.460B | 0.00 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |